Headache and the Pseudotumor Cerebri Syndrome

Current Pain and Headache Reports

Volumn 18, Issue 9, 2014, Pages

  Mallery, Robert M ^a   Friedman, Deborah I ^b   Liu, Grant T ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Idiopathic intracranial hypertension (IIH); Papilledema; Pseudotumor cerebri syndrome (PTCS); Secondary headache; Treatment

Indexed keywords

ACETAZOLAMIDE; DIURETIC AGENT; FRUCTOSE; FUROSEMIDE; NEUROPROTECTIVE AGENT; TOPIRAMATE;

ANALOGS AND DERIVATIVES; BACK PAIN; COMPLICATION; DIFFERENTIAL DIAGNOSIS; HEADACHE DISORDERS; HUMAN; INTRACRANIAL HYPERTENSION; MIGRAINE DISORDERS; PAPILLEDEMA; PATHOPHYSIOLOGY; PSEUDOTUMOR CEREBRI; TINNITUS; VISION DISORDERS; WEIGHT REDUCTION;

ACETAZOLAMIDE; BACK PAIN; DIAGNOSIS, DIFFERENTIAL; DIURETICS; FRUCTOSE; FUROSEMIDE; HEADACHE DISORDERS; HUMANS; INTRACRANIAL HYPERTENSION; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; PAPILLEDEMA; PSEUDOTUMOR CEREBRI; TINNITUS; VISION DISORDERS; WEIGHT REDUCTION PROGRAMS;

EID: 84928053428     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-014-0446-z     Document Type: Review

References (55)

1. Rangwala LM, Liu GT. Pediatric idiopathic intracranial hypertension. Surv Ophthalmol. 2007;52:597–617.
2. Balcer LJ, Liu GT, Forman S, et al. Idiopathic intracranial hypertension: relation of age and obesity in children. Neurology. 1999;52:870–2.
3. Wall M. The headache profile of idiopathic intracranial hypertension. Cephalalgia. 1990;10:331–5.
4. Giuseffi V, Wall M, Siegel PZ, Rojas PB. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case–control study. Neurology. 1991;41:239–44.
5. Johnston I, Paterson A. Benign intracranial hypertension. II. CSF pressure and circulation. Brain. 1974;97:301–12.
6. Wang SJ, Silberstein SD, Patterson S, Young WB. Idiopathic intracranial hypertension without papilledema: a case–control study in a headache center. Neurology. 1998;51:245–9.
7. Wall M, Kupersmith MJ, kieburts KD, et al. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA neurology 2014;71:693-701. This study describes the baseline clinical characteristics of the IIH Treatment Trial.
8. Mathew NT, Ravishankar K, Sanin LC. Coexistence of migraine and idiopathic intracranial hypertension without papilledema. Neurology. 1996;46:1226–30.
9. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology. 2006;67:252–7.
10. Ravid S, Shahar E, Schiff A, Gordon S. Obesity in children with headaches: association with headache type, frequency, and disability. Headache. 2013;53:954–61.
11. Peterlin BL, Rosso AL, Williams MA, et al. Episodic migraine and obesity and the influence of age, race, and sex. Neurology. 2013;81:1314–21.
12. Chai NC, Scher AI, Moghekar A, Bond DS, Peterlin BL. Obesity and headache: part I—a systematic review of the epidemiology of obesity and headache. Headache. 2014;54:219–34. This literature review discusses the relationship between obesity and primary and secondary headache disorders.
13. Biousse V, Ameri A, Bousser MG. Isolated intracranial hypertension as the only sign of cerebral venous thrombosis. Neurology. 1999;53:1537–42.
14. Lepore FE. Unilateral and highly asymmetric papilledema in pseudotumor cerebri. Neurology. 1992;42:676–8.
15. Huna-Baron R, Landau K, Rosenberg M, Warren FA, Kupersmith MJ. Unilateral swollen disc due to increased intracranial pressure. Neurology. 2001;56:1588–90.
16. Friedman DI, Forman S, Levi L, Lavin PJ, Donahue S. Unusual ocular motility disturbances with increased intracranial pressure. Neurology. 1998;50:1893–6.
17. Bortoluzzi M, Di Lauro L, Marini G. Benign intracranial hypertension with spinal and radicular pain. Case report. J Neurosurg. 1982;57:833–6.
18. Comabella M, Montalban J, Lozano M, Codina A. Lhermitte’s sign in pseudotumour cerebri. J Neurol. 1995;242:610–1.
19. Fay T. A new test for the diagnosis of certain headaches: the cephalogram. Dis Nerv Syst. 1940;1:312–5.
20. Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81:1159–65. This article introduces a revision to the terminology and diagnostic criteria for PTCS.
21. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.
22. McGeeney BE, Friedman DI. Pseudotumor cerebri pathophysiology. Headache. 2014;54:445–58. This review article discusses the pathophysiology of primary PTCS, including a discussion of hormonal effects on CSF outflow resistance.
23. Gjerris F, Soelberg Sorensen P, Vorstrup S, Paulson OB. Intracranial pressure, conductance to cerebrospinal fluid outflow, and cerebral blood flow in patients with benign intracranial hypertension (pseudotumor cerebri). Ann Neurol. 1985;17:158–62.
24. Janny P, Chazal J, Colnet G, Irthum B, Georget AM. Benign intracranial hypertension and disorders of CSF absorption. Surg Neurol. 1981;15:168–74.
25. Mann JD, Johnson RN, Butler AB, Bass NH. Impairment of cerebrospinal fluid circulatory dynamics in pseudotumor cerebri and response to steroid treatment. Neurology. 1979;29:550.
26. Wall M. Idiopathic intracranial hypertension and the idiopathic intracranial hypertension treatment trial. J Neuroophthalmol. 2013;33:1–3.
27. McGonigal A, Bone I, Teasdale E. Resolution of transverse sinus stenosis in idiopathic intracranial hypertension after LP shunt. Neurology. 2004;62:514–5.
28. Bono F, Giliberto C, Mastrandrea C, et al. Transverse sinus stenoses persist after normalization of the CSF pressure in IIH. Neurology. 2005;65:1090–3.
29. Ahmed RM, Zmudzki F, Parker GD, Owler BK, Halmagyi GM. Transverse sinus stenting for pseudotumor cerebri: a cost comparison with CSF shunting. AJNR Am J Neuroradiol. 2013.
30. Stevens SA, Stimpson J, Lakin WD, Thakore NJ, Penar PL. A model for idiopathic intracranial hypertension and associated pathological ICP wave-forms. IEEE Trans Biomed Eng. 2008;55:388–98.
31. Bateman GA, Stevens SA, Stimpson J. A mathematical model of idiopathic intracranial hypertension incorporating increased arterial inflow and variable venous outflow collapsibility. J Neurosurg. 2009;110:446–56.
32. Daniels AB, Liu GT, Volpe NJ, et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol. 2007;143:635–41.
33. Johnson LN, Krohel GB, Madsen RW, March Jr GA. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology. 1998;105:2313–7.
34. Ko MW, Chang SC, Ridha MA, et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case–control study. Neurology. 2011;76:1564–7. This case–control study demonstrates that weight gain is associated with recurrence of PTCS.
35. Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ. 2010;341:c2701.
36. Sugerman HJ, Felton 3rd WL, Salvant Jr JB, Sismanis A, Kellum JM. Effects of surgically induced weight loss on idiopathic intracranial hypertension in morbid obesity. Neurology. 1995;45:1655–9.
37. Rubin RC, Henderson ES, Ommaya AK, Walker MD, Rall DP. The production of cerebrospinal fluid in man and its modification by acetazolamide. J Neurosurg. 1966;25:430–6.
38. Ball AK, Howman A, Wheatley K, et al. A randomised controlled trial of treatment for idiopathic intracranial hypertension. J Neurol. 2011;258:874–81.
39. Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA J Am Med Assoc. 2014;311:1641–1651. This is a randomized-controlled trial comparing visual field function in patients with IIH and mild vision loss treated with acetazolamide and weight-reduction diet versus diet alone.
40. Schoeman JF. Childhood pseudotumor cerebri: clinical and intracranial pressure response to acetazolamide and furosemide treatment in a case series. J Child Neurol. 1994;9:130–4.
41. McCarthy KD, Reed DJ. The effect of acetazolamide and furosemide on cerebrospinal fluid production and choroid plexus carbonic anhydrase activity. J Pharmacol Exp Ther. 1974;189:194–201.
42. Celebisoy N, Gokcay F, Sirin H, Akyurekli O. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand. 2007;116:322–7.
43. Banta JT, Hoffman K, Budenz DL, Ceballos E, Greenfield DS. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol. 2001;132:112–4.
44. Craig JE, Ong TJ, Louis DL, Wells JM. Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma. Am J Ophthalmol. 2004;137:193–5.
45. Bynke G, Zemack G, Bynke H, Romner B. Ventriculoperitoneal shunting for idiopathic intracranial hypertension. Neurology. 2004;63:1314–6.
46. Rosenberg ML, Corbett JJ, Smith C, et al. Cerebrospinal fluid diversion procedures in pseudotumor cerebri. Neurology. 1993;43:1071–2.
47. Burgett RA, Purvin VA, Kawasaki A. Lumboperitoneal shunting for pseudotumor cerebri. Neurology. 1997;49:734–9.
48. Eggenberger ER, Miller NR, Vitale S. Lumboperitoneal shunt for the treatment of pseudotumor cerebri. Neurology. 1996;46:1524–30.
49. McGirt MJ, Woodworth G, Thomas G, Miller N, Williams M, Rigamonti D. Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes. J Neurosurg. 2004;101:627–32.
50. Corbett JJ, Nerad JA, Tse DT, Anderson RL. Results of optic nerve sheath fenestration for pseudotumor cerebri. The lateral orbitotomy approach. Arch Ophthalmol. 1988;106:1391–7.
51. Spoor TC, McHenry JG. Long-term effectiveness of optic nerve sheath decompression for pseudotumor cerebri. Arch Ophthalmol. 1993;111:632–5.
52. Goh KY, Schatz NJ, Glaser JS. Optic nerve sheath fenestration for pseudotumor cerebri. J Neuroophthalmol. 1997;17:86–91.
53. Ahmed R, Friedman DI, Halmagyi GM. Stenting of the transverse sinuses in idiopathic intracranial hypertension. J Neuroophthalmol. 2011;31:374–80.
54. Higgins JN, Cousins C, Owler BK, Sarkies N, Pickard JD. Idiopathic intracranial hypertension: 12 cases treated by venous sinus stenting. J Neurol Neurosurg Psychiatry. 2003;74:1662–6.
55. Radvany MG, Solomon D, Nijjar S, et al. Visual and neurological outcomes following endovascular stenting for pseudotumor cerebri associated with transverse sinus stenosis. J Neuroophthalmol. 2013;33:117–22.